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Summary.-Pulmonary growths produced by intravenous injection of methycholan-
threne-induced sarcoma cells were controlled or suppressed by specific immuno-
stimulation with BCG-sarcoma cell inocula at subcutaneous sites or by intravenous
treatment with BCG alone. The response was dependent upon the immunogenicity
of the treated tumour so that in comparison, intravenous injection of BCG enhanced
rather than suppressed pulmonary growths of transferred cells of several weakly
immunogenic tumours including a spontaneously arising sarcoma and an epithe-
lioma as well as a carcinogen-induced mammary carcinoma.
STUDIES with guinea-pig hepatomata
(Zbar, Bernstein and Rapp, 1971) and
3-methylcholanthrene (Mc)-induced sar-
comata in rats (Baldwin and Pimm, 1971)
and mice (Bartlett, 1971; Bartlett, Zbar
and Rapp, 1972) have established that
subcutaneous or intradermal implantation
of tumour cells in admixture with viable
Bacillus Calmette Guerin (BCG) organisms
prevents their growth in genetically com-
patible hosts. Furthermore, deliberate
infection ofestablished local tumours may
also lead to their suppression (Baldwin
and Pimm, 1971; Zbar and Tanaka, 1971),
and, with guinea-pig hepatomata, to the
inhibition of lymph node metastasis
(Zbar and Tanaka, 1971).
The mechanism of this tumour inhibi-
tion is still not understood, although
factors other than general immunostimu-
lation are involved, since intimate contact
betweenBCGand tumour cells isnecessary
to suppress tumour growth (Baldwin and
Pimm, 1971; Zbar et al., 1971; Bartlett et
al., 1972). Nevertheless, specific responses
to tumour-associated rejection antigens
may be evoked, since rejection of cells of
rat sarcomata (Baldwin and Pimm, 1971)
and guinea-pig hepatomata (Zbar et al.,
1971) in admixture with BCG provides
protection against challenge with cells of
the same tumour, but not other anti-
genically distinct tumours.
The objective ofthe present investiga-
tion was to explore immunotherapeutic
methods with BCG for the treatment of
pulmonary deposits of tumour, produced
by intravenous transfer of tumour cells.
Whilst it is recognized that this mode of
producing tumourgrowth inthelungs may
differ from that occurring during spon-
taneous pulmonary metastasis, it has
allowed a comparison of the effectiveness
of BCG in the treatment of disseminated
rat tumour cells of different histological
types, with defined immunogenicities,
ranging from highly immunogenic Mc-
induced sarcomata, to weakly or non-
immunogenic chemically-induced or
spontaneously arising tumours.
MATERIALS AND METHODS
Tumours
The tumours used in these studies were
induced with chemical carcinogens or arose
without deliberate induction in rats of an
inbred Wistar strain. Each tumour was
carried by subcutaneous transplantation in
syngeneic rats ofthe same sex as the primary
donor. The following tumours were used:
(i) Sarcomata Mc7, Mc4OA and Mc52A
induced by subcutaneous injection of 3-BCOG IMMUNOTHERAPY OF PULMONARY GROWTHS
methylcholanthrene. These tumours were
highly antigenic, animals immunized by
excision of subcutaneous growths subse-
quently rejecting challenge with whole
tumour grafts.
(ii) MammarycarcinomaAAF57-induced
by oral administration of N-hydroxy-2-
acetylaminofluorene. This tumour lacked
significant antigenicity, since excision of
subcutaneous grafts did not elicit resistance
against a subsequent challenge with 5 x 104
viable cells.
(iii) Sarcoma Sp24-a fibrosarcoma, aris-
ing spontaneously and weakly immunogenic,
immunized rats rejecting only 103 viable
cells.
(iv) Epithelioma Spl-arose spontane-
ously and exhibited low antigenicity, no
more than 5 x 104 cells being rejected by
immunized rats.
Single cell suspensions of tumours were
prepared by digestion of finely minced tissue
with 0-25% trypsin in Hank's balanced salt
solution and resuspension in medium 199.
Pulmonary growth of tumours was produced
by intravenous injection of single cell
suspensions into a lateral tail vein.
Bacillus Calmette Gue'rin (BCG)
Freeze-dried BCG vaccine (Percutaneous)
was supplied by Glaxo Laboratories Ltd.,
Greenford, Middlesex, England. The vaccine
was reconstituted in water to 10 mg moist
weight of organisms/ml.
Methods of treatment
Active immunotherapy of intravenously
transferred tumour cells was given by single
orrepeated subcutaneous injections oftumour
cells in admixture with viable BCG, growth
of these inocula being completely prevented.
Adjuvant immunotherapy by systemic
BCG infection was effected by single or
repeated intravenous injections of BCG (0.1
mg to 1 0 mg moist weight). When this
treatment was given at the same time as
intravenous tumour cell injection, BCG and
tumour cells were injected in admixture.
Assessment ofpulmonary tumour growth
Pulmonary growth ofintravenously trans-
ferred tumour cells was demonstrated by
perfusion of lungs with diluted Indian ink,
followed by fixation in Fekete's solution
(Wexler, 1966), and the number of macro-
scopic nodules on the lung surface counted.
In those experiments where the influence
of BCG treatment on survival after intra-
venous injection of tumour cells was
examined, animals were killed individually
when they became distressed due to pulmon-
ary tumour growth. Survival times were
calculated with respect to the day of tumour
cell injection.
RESULTS
Immunotherapy of pulmonary deposits of
3-methylcholanthrene-induced sarcomata
Active immunotherapy.-In the initial
series of experiments, cells of Mc-induced
sarcomata were injected intravenously and
their pulmonary growth treated by active
immunotherapy. This was given by the
TABLE I.-Active Immunotherapy ofIntravenously Transferred Rat Sarcoma Cells
No. cells
Treatment
t_
Ex
termii
Expt. Sarcoma injected Day* Inoculumt (da
1 Mc4OA 5x106 0 1-5 mg BCG+ 1
5 x 106 Mc40A cells
5X106 1
2 Mc40A 5x 105 0 1- 0mg BCG+ 1
3 x 106 Mc40A cells
5x 105 - 1
3 Mc52A Ix106 0 1 0mgBCG+Ix106 2
Mc52A cells
1x106 10 I 0 mg BCG+1 x106 2
Mc52A cells
x106 - 2
4 Mc52A 2x106 0 1 0 mg BCG+2x106 4
Mc52A cells
2x106 - 4
* With respect to tumour cell injection.
t Viable sarcoma cells in admixture with BCG injected subcutaneously.
.pt.
inated
Iy*)
14
No. rats
with lung
tumours
1/5
No.
nodules/
lung
lx 200+
14 5/5 5x 200+
19 1/4 1x70
19 4/5 4x200+
11 2/4 48, 200+
q1 2/4 75, 200+
1' 4/4 3, 3x200+
L1 0/5 -
L1 3/4 2, 3, 20
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subcutaneous injection of viable cells of
the same tumour (1 to 5 x 106 cells) in
admixture with BCG (1P0 to 1-5 mg moist
weight), since it has been established that
such inocula do not develop and produce
an effective immune response capable of
suppressing subcutaneous sarcoma growth
at a distant site (Baldwin and Pimm,
1971). The results, summarized in Table
I, clearly indicate that when sarcoma cells
and BCG were inoculated subcutaneously
at the same time as tumour cells were
given intravenously, pulmonary tumour
growth was inhibited.
In experiment 1, 5 x 106 sarcoma
Mc4OA cells were injected intravenously,
and the rats simultaneously received a
subcutaneous injection of 5 x 106 viable
Mc4OA cells mixed with 1 5 mg moist
weight of BCG. The experiment was
terminated 14 days later, since control
rats showed respiratory distress, all having
multiple (200+) tumour nodules in the
lungs. In contrast, only one of 5 animals
receiving immunotherapy lhad pulmonary
deposits of tumour.
In 3 further experiments with sar-
comata Mc4OA and Mc52A, active
immunotherapy prevented pulmonary
tumour development in the majority
(12/17) of animals. Furthermore, with
sarcoma McO52A partial suppression was
obtained even when treatment was delayed
until 10 days after intravenous injection
of sarcoma cells (experiment 3).
Adjuvant immunotherapy.--Previous
studies (Baldwin and Pimm, 1971) showed
that direct contact between BCG
organisms and sarcoma cells was necessary
to inhibit local tumour growth. Tests
were therefore carried out to evaluate
whether pulmonary growth of intra-
venously transferred sarcoma cells could
be inhibited by systemic treatment with
BCG, itself administered intravenously.
In these tests sarcoma cells (5 x 105 to
5 x 106) were inoculated intravenously in
admixture with BCG (0.1 mg or 10 mg
moist weight), or BCG (1.0 mg moist
weight) was injected separately 5 to 7
days after tumour cell injection (Table II).
Almost all (30/32) control rats developed
pulmonary tumour nodules, so that the
experiments had to be terminated 14 to
41 days after tumour cell injections. In
contrast only 3/56 animals receiving an
intravenous injection of BCG, either
together with the tumour cells, or 5 to 7
TABLE II.- BCG Adjuvant Treatment of Intravenously Transferred Rat Sarcoma Cells
BCG treatment
Expt. Sarcoma
1 Mc4OA
2 Mc40A
No. cells
injectecd
5 x 106
5x 105
3 Mlc4OA 5 x 105
4 Mc4OA 5x105
5 Mlc7 2 x 106
6 Mc52A x 106
7 Mc52A 2x 106
* With respect to turnoui cell injection.
Dose Expt.
(mg moist terminated
Day* weight) (day*)
'-- 14
0 1-0 14
19
O 1t0 19
5 1-0 19
21
0 1.0 21
6 1-0 21
32
o 1.0 32
0 0o1 32
14
0 1.0 14
7 1 0 14
21
0 1.0 21
6 1.0 21
41
0 1.0 41
No. rats
wxith lung
tumours
5/5
0/5
4/5
0/5
0/5
5/5
0/5
0/5
5/5
3/5
0/5
4/4
0/4
0/4
4/4
0/4
0/5
3/4
0/4
No. nodules/lung
5 x 200+
4 x 200+
40, 140, 3x200+
5, 31, 73, 100, 120
2, 6, 13
40, 140, 2 x 200+
3, 3 x 200+
2, 3, 20
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TABLE III. IMn
Expt. Dayt
1 0,3,5,7
0, 5, 10
24 0, 6, 10, 12
6, 10, 12, 15
0
mun(
Treatment
urviva
Route Inoculum (days)
I.V. 4x 1 mg BCG 49, 52, 52, 94, 129
(Mean 75)
S.C. 3 x I mg BCG 33, 43, 48, 54
+ 2 x MIc4OA cells (Mean 44)
25, 31, 32, 33
(Mean 30)
I.V. 4x I mg BCG 57, 4x 100
(Mean 91)
IAT. 4x 1 mg BCG 56, 57, 2 x 100
(Mean 78)
I.V. I x I mg BCG 4x 100
(Mean 100)
21, 21, 22, 37
(AMean 25)
* 5 x 105 sarcoma Mc4OA cells
t WXith respect to ttumouir cell injection.
. Experiment terminated at Day 100.
days later, had macroscopic tumour
nodules in the lungs when the experiments
were terminated.
In a further series of experiments with
sarcoma Mc4OA, an assessment was made
of the effect of immunotherapy on the
survival of rats following the intravenous
injection of tumour cells (Table III).
Both active immunotherapy and systemic
treatment with BCG markedly prolonged
survival following the intravenous injec-
tion of 5 x 105 sarcoma cells.
In experiment 1, control animals had
to be killed 25 to 33 days (mean 30 days)
after intravenous tumour cell injection
due to the development of multiple
pulmonary deposits (116 to 200 nodules/
lung). Animals receiving 3 subcutaneous
injections of 2 x 106 viable Mc4OA cells
in admixture with BCG (b10 mg moist
weight) at 5-day intervals survived for 33
to 54 days (mean 44 days) and had fewer
lung tumour nodules (45 to 200 nodules).
Four intravenous injections of BCG (1.0
mg moist weight) at 2 to 3 day intervals,
starting at the time ofintravenous tumour
cell injection, produced a more marked
prolongation of survival (49 to 129 days,
mean 75 days) and a considerable reduc-
tion in the numbers of pulmonary tumour
nodules (0 to 30 nodules).
In the second experiment, control
animals survived for 21 to 37 days (meain
No. rats
w-ith lung
tumours
4/5
4/4
4/4
1/5
0/4
2/4
4/4
No.
nodules/lung
2, 6, 10, 30
45, 72, 120, 200+
116, 3x200+
4
1, 2
130, 3 x 200+
23 days) and developed multiple pulmon-
ary tumour deposits (130 to 200 nodules/
lung). A single injection of BCG at the
same time as tumour cell injection, or
repeated administration starting up to 6
days later, again significantly prolonged
survival and markedly reduced the num-
bers ofpulmonary tumour deposits. Thus
only 3/13 treated rats developed tumour
nodules in the lung (1 to 4 nodules/lung),
the majority of animals remaining healthy
and tumour free for 100 days, at which
time the experiment was terminated.
Immunotherapy of pulmonary deposits of
other tumours
In view of the inhibitory effect of the
systemically administered BCG on the
growth of intravenously transferred cells
of highly immunogenic sarcomata, the
effectiveness ofthis form of treatment was
evaluated using tumours with lower
immunogenicities. In these tests, tumour
cells (1 x 103 to 1 x 105) were injected
intravenously in admixture with BCG
(0.5 mg to 1P0 mg moist weight) and in
some cases, rats received 2 further BCG
injections at 3 to 4 day intervals (Table
IV).
With all 3 tumours tested, pulmonary
tumour growth was consistently enhanced
rather than inhibited by BCG treatment.
Thus in 2 tests with mammary carcinoma
,otherapy of Intravenously Transferred Sarcoma ]Ic4OA Cells*
51-R. W. BALDWIN AND M. V. PIMM
0i
0
01)
o o 0
+ lo +0+ 10 C
C O C) 1 1 co
x ~x x
CO 02CO10 -0 COm
0~0 1 03
~c 01t o
-
> *E Ca E Cs E Ca
5
.. g:j
F-4H H H
01 00 0
(~ I~ IA
x
CO
.0 O
-4
x
-4
4- -4 -4 -
xxx xx
,*-0 -4 -0 -
CO-
CO CO 1
CO _C10D
.0 .CO
10 C CD
0 0
10 0 O0C
COo0
0 0
x
0
x
EH ;
o
a
E o ¢ . in SSO
0 r 3C -
0
0
E E E o
0 0 P S) S) "I '
.0
10 CO 1XID to t-
52
o0
0:
to
01
oc ^ 01
1 0-
N -
N X
N Ni
C-D °°
CO
CO
CO
N
01~
01
01-
01
fm - 0
S, E
C,3
0
CO
CO
0
0
1.t
cO 01
t c0 14^ - (M -
c t C9
0 CO
C4 cO~
0101
(1)
.
H 9
C ."
.z
0 c
02
.E--'
0
C
-4 -4 -
xx x
-
I
;~ S4 C
C2C2 -
x
O 0
C> O O A I_
-4
x
1-
x
1-
0
x
1-
0
o
- - -
C)BCG IMMUNOTHERAPY OF PULMONARY GROWTHS
AAF57 (experiments 1 and 2), control rats
developed 9 to 72 lung tumour nodules
following intravenous injection of 1 X 105
tumour cells. Single or repeated injection
ofBCG caused an enhancement oftumour
growth so that all treated rats had in
excess of 200 tumour nodules. Compar-
able BCG treatment enhanced growth of
epithelioma Spl and fibrosarcoma Sp24
as assessed from the numbers of lung
tumour nodules or the survival times of
treated rats. For example, in one test
with tumour Sp24, intravenous injection
of 1 x 103 tumour cells did not produce
lung tumour nodules whereas a simul-
taneous injection of BCG enhanced
pulmonary tumour growth.
DISCUSSION
These studies demonstrate that growth
of pulmonary deposits of immunogenic
Mc-induced sarcomata can be markedly
suppressed by the injection at a subcu-
taneous site of viable sarcoma cells in
admixture with BCG. Under these con-
ditions, local tumour growth is prevented
and leads to the development of a specific
active immunization which has been
shown previously (Baldwin and Pimm,
1971) to elicit concomitant rejection of
cells of the same tumour injected into a
contralateral site. In this situation,
therefore, suppression of pulmonary
tumour growth also may be due to a
specific immunization, and is consistent
with the reports on active immunotherapy
using irradiated tumour cells together
with BCG (Eilber, Holmes and Morton,
1971; Mathe, Pouillart and Lapeyraque,
1969; Parr, 1972). Whetherviabletumour
cells prevented from progressive growth
by contact with BCG are more effective in
immunotherapy than irradiated tumour
cells alone or with adjuvants, has still to
be evaluated.
More markedsuppression ofpulmonary
tumour growth from intravenously in-
jected Mc-induced sarcomata was
achieved by single or repeated intra-
venous injections of BCG vaccine, even
when treatment was initiated up to 7
days after tumour cell injection. This was
indicated by the almost total inhibition of
pulmonary tumour nodules after 14 to 41
days in treated rats, whereas the majority
ofcontrols showed extensive lung tumours
(Table II). Moreover, in experiments
with sarcoma Mc4OA, rats injected intra-
venously with BCG survived significantly
longer than untreated controls (Table III).
In previous studies with Mc-induced
sarcomata in rats (Baldwin and Pimm,
1971) and mice (Bartlett et al., 1972)
direct contact between BCG organisms
and tumour cells was a necessary require-
ment for suppression of tumour growth.
The design of the present tests was based
on the finding that intravenously injected
mycobacterial cells show preferential
survival in lungs (Lefford, 1971) and may
therefore come into contact with pulmon-
ary tumour deposits. The mechanism
whereby direct contact between tumour
cells and BCG organisms results in sup-
pression oftumour growth is still undeter-
mined. The effect does not represent
direct cytotoxicity of BCG or extra-
cellular products since the organisms are
not cytotoxic for mouse sarcoma cells
(Bartlett et al., 1972) and do not inhibit
growth of rat tumours in tissue culture
(Baldwin, Pimm and Robins, unpublished
findings). Moreover, whereas general
stimulation of the reticuloendothelial sys-
tem may play a contributory role,
comparable with the partial suppression
of tumour growth observed in other
studies (Mathe et al., 1969; Parr, 1972;
Rios and Simmons, 1972), the more
marked suppression requires direct contact
between BCG and tumour cells, suggesting
that one of the functions of the BCG is to
enhance local responses to tumour-specific
antigens. This concept is supported by
the present studies showing a correlation
between the effectiveness of BCG in
inhibiting pulmonary tumour growth and
the immunogenicity of the target tumour.
For example, pulmonary growth of im-
munogenic Mc-induced sarcomata was
almost completely suppressed by intra-
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venous injection of the BCG whereas
comparable treatment had no positive
effect on the weakly immunogenic sarcoma
Sp24 and even led to enhanced tumour
growth (Table IV).
It is well established that an acute
granulomatous response can be induced in
the lungs of mice by the intravenous
injection of mycobacteria (Youmans and
Youmans, 1964). Possibly, therefore, the
accumulation of macrophages may be the
initial response leading to tumour rejec-
tion, especially in view ofrecent reports on
the tumour inhibitory activity ofactivated
macrophages (Evans and Alexander, 1972;
Keller and Jones, 1971). In relation to
immunotherapy, however, a more practi-
cal question relates to the use of
inactivated mycobacterial preparations
such as heat killed or irradiated organisms,
or possibly, subcellular fractions (Zbar,
Rapp and Ribi, 1972) and this is currently
being studied using the experimental rat
tumours described in this paper. In
addition the efficacy of BCG immuno-
therapy is being evaluated using
epithelioma Spl which spontaneously
produces pulmonary metastases following
subcutaneous implantation, since this
approximates more closely to the clinical
situation.
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